AIM: To investigate the potential mechanism of Arg- Gly-Asp (RGD) peptide-labeled liposome loading oxy- matrine (OM) therapy in CCI4-induced hepatic fibrosis in rats. METHODS: We constructed a rat model of CCh- ...AIM: To investigate the potential mechanism of Arg- Gly-Asp (RGD) peptide-labeled liposome loading oxy- matrine (OM) therapy in CCI4-induced hepatic fibrosis in rats. METHODS: We constructed a rat model of CCh- induced hepatic fibrosis and treated the rats with dif- ferent formulations of OM. To evaluate the antifibrotic effect of OM, we detected levels of alkaline phospha- tase, hepatic histopathology (hematoxylin and eosin stain and Masson staining) and fibrosis-related gene expression of matrix metallopeptidase (MMP)-2, tis- sue inhibitor of metalloproteinase (TIMP)-I as well as type I procollagen via quantitative real-time poly- merase chain reaction. To detect cell viability and apop- tosis of hepatic stellate cells (HSCs), we performed 3-(4,5)-dimethylthiahiazo(-z-yl)-3,5-diphenytetrazoli- umromide assay and flow cytometry. To reinforce the combination of oxymatrine with HSCs, we constructed fluorescein-isothiocyanate-conjugated Arg-Gly-Asp peptide-labeled liposomes loading OM, and its targeting of HSCs was examined by fluorescent microscopy. RESULTS: OM attenuated CCh-induced hepatic fibro- sis, as defined by reducing serum alkaline phosphatase (344.47± 27.52 U/L vs 550.69 ± 43.78 U/L, P 〈 0.05), attenuating liver injury and improving collagen deposits (2.36% ± 0.09% vs 7.70% ±0.60%, P 〈 0.05) and downregulating fibrosis-related gene expression, that is, MMP-2, TIMP-1 and type I procollagen (P 〈 0.05). OM inhibited cell viability and induced apoptosis of HSCs in vitro. RGD promoted OM targeting of HSCs and en- hanced the therapeutic effect of OM in terms of serum alkaline phosphatase (272.51 ± 19.55 U/L vs 344.47 ± 27.52 U/L, P 〈 0.05), liver injury, collagen deposits (0.26%± 0.09% vs 2.36% ± 0.09%, P 〈 0.05) and downregulating fibrosis-related gene expression, that is, MMP-2, TIMP-1 and type I procollagen (P 〈 0.05). Moreover, in vitro assay demonstrated that RGD en- hanced the effect of OM on HSC viability and apoptosis. CONCLUSION: OM attenuated hepatic fibrosis by in- hibiting viability and inducing apoptosis of HSCs. The RGD-labeled formulation enhanced the targeting effi- ciency for HSCs and the therapeutic effect.展开更多
基金Supported by National Natural Science Foundation of China,No. 30600848
文摘AIM: To investigate the potential mechanism of Arg- Gly-Asp (RGD) peptide-labeled liposome loading oxy- matrine (OM) therapy in CCI4-induced hepatic fibrosis in rats. METHODS: We constructed a rat model of CCh- induced hepatic fibrosis and treated the rats with dif- ferent formulations of OM. To evaluate the antifibrotic effect of OM, we detected levels of alkaline phospha- tase, hepatic histopathology (hematoxylin and eosin stain and Masson staining) and fibrosis-related gene expression of matrix metallopeptidase (MMP)-2, tis- sue inhibitor of metalloproteinase (TIMP)-I as well as type I procollagen via quantitative real-time poly- merase chain reaction. To detect cell viability and apop- tosis of hepatic stellate cells (HSCs), we performed 3-(4,5)-dimethylthiahiazo(-z-yl)-3,5-diphenytetrazoli- umromide assay and flow cytometry. To reinforce the combination of oxymatrine with HSCs, we constructed fluorescein-isothiocyanate-conjugated Arg-Gly-Asp peptide-labeled liposomes loading OM, and its targeting of HSCs was examined by fluorescent microscopy. RESULTS: OM attenuated CCh-induced hepatic fibro- sis, as defined by reducing serum alkaline phosphatase (344.47± 27.52 U/L vs 550.69 ± 43.78 U/L, P 〈 0.05), attenuating liver injury and improving collagen deposits (2.36% ± 0.09% vs 7.70% ±0.60%, P 〈 0.05) and downregulating fibrosis-related gene expression, that is, MMP-2, TIMP-1 and type I procollagen (P 〈 0.05). OM inhibited cell viability and induced apoptosis of HSCs in vitro. RGD promoted OM targeting of HSCs and en- hanced the therapeutic effect of OM in terms of serum alkaline phosphatase (272.51 ± 19.55 U/L vs 344.47 ± 27.52 U/L, P 〈 0.05), liver injury, collagen deposits (0.26%± 0.09% vs 2.36% ± 0.09%, P 〈 0.05) and downregulating fibrosis-related gene expression, that is, MMP-2, TIMP-1 and type I procollagen (P 〈 0.05). Moreover, in vitro assay demonstrated that RGD en- hanced the effect of OM on HSC viability and apoptosis. CONCLUSION: OM attenuated hepatic fibrosis by in- hibiting viability and inducing apoptosis of HSCs. The RGD-labeled formulation enhanced the targeting effi- ciency for HSCs and the therapeutic effect.